Calliditas Therapeutics AB logo

CALT

Calliditas Therapeutics AB

$23.06

Earnings Summary

Revenue
$0Mn
Net Profits
$-61.33Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Calliditas Therapeutics AB’s revenue fell -100% since last year same period to $0Mn in the Q2 2020. On a quarterly growth basis, Calliditas Therapeutics AB has generated -100% fall in its revenue since last 3-months.

Net Profits:

Calliditas Therapeutics AB’s net profit fell -173.74% since last year same period to $-61.33Mn in the Q2 2020. On a quarterly growth basis, Calliditas Therapeutics AB has generated 3.75% jump in its net profits since last 3-months.

Net Profit Margins:

Calliditas Therapeutics AB’s net profit margin fell -Inf% since last year same period to -Inf% in the Q2 2020. On a quarterly growth basis, Calliditas Therapeutics AB has generated -Inf% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Calliditas Therapeutics AB post its latest quarter earnings

EPS Estimate Current Quarter
0.27
EPS Estimate Current Year
0.27

Highlights

EPS Estimate Current Quarter:

Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current quarter stand at 0.27 - a 178.77% jump from last quarter’s estimates.

EPS Estimate Current Year:

Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current year stand at 0.27.

Key Ratios

Key ratios of the Calliditas Therapeutics AB post its Q1 2023 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Calliditas Therapeutics AB’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the Calliditas Therapeutics AB has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2019-09-30
0
-0.27
-Inf%
2019-06-30
0
0.49
+Inf%
2019-03-31
0
-0.25
-Inf%
2019-12-31
0
-0.12
-Inf%

Company Information

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Organisation
Calliditas Therapeutics AB
Headquarters
Kungsbron 1, D5, Stockholm, Sweden, 111 22
Employees
102
Industry
Health Technology
CEO
Renee J. Aguiar-Lucander